DENVER, Colo., Nov 03, 2025 (247marketnews.com)- Markets open the week with a wave of high-impact biotech and healthcare developments, highlighting innovation across cancer therapy, women’s health, and sustainable materials.
Iovance Biotherapeutics (NASDAQ:IOVA) reported interim data from its registrational Phase 2 IOV-LUN-202 trial, showing a 26% objective response rate (ORR) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) previously treated with immunotherapy and chemotherapy.
The most striking outcome: the median duration of response was not reached after 25 months of follow-up, suggesting deep and durable remissions. For comparison, standard-of-care docetaxel in this setting yields only a 12.8% ORR and median DOR of 5.6 months.
Lifileucel, Iovance’s tumor infiltrating lymphocyte (TIL) cell therapy, could emerge as the first effective one-time cellular therapy in post-checkpoint inhibitor NSCLC. Regulatory progression toward a supplemental Biologics License Application (sBLA) is expected in 2026, with a potential launch targeted for the second half of 2027.
Phio Pharmaceuticals (NASDAQ:PHIO) announced pathologic results from its Phase 1b PH-762 skin cancer trial, showing 100% tumor clearance in one patient, >90% clearance in a second, and >50% in a third, all within five weeks of treatment.
The Safety Monitoring Committee also reported no dose-limiting toxicities at the trial’s maximum dose, confirming a strong safety profile across five escalating cohorts. Phio’s INTASYL® platform, designed to silence gene expression within tumor cells, continues to demonstrate proof of concept for non-surgical, RNA-based immuno-oncology therapies.
Kraig Biocraft Laboratories (OTCQB:KBLB) is preparing to deliver its first spider silk fiber and fabric samples to three industry partners, two in performance apparel and one in luxury textiles.
These shipments will represent the company’s first commercial sales, marking a turning point after nearly two decades of development. In fashion, sample quantities of 50–500 kilograms are standard for pre-contract validation, signaling that Kraig Labs has reached true production scale.
Spider silk, five times stronger than steel by weight yet biodegradable, is poised to disrupt the $6.5 billion sustainable textile market, where brands face growing mandates to replace plastics and synthetics. 24/7 Market News calls this “the official start of the spider silk race,” with Kraig leading a field of global competitors.
Femasys (NASDAQ:FEMY) announced FDA IDE approval to advance the final pivotal phase of its FemBloc trial, a first-of-its-kind, non-surgical permanent birth control system.
Coupled with a $12 million private placement financing (and up to $58 million potential proceeds if all warrants are exercised), Femasys now has a clear runway toward potential FDA Pre-Market Approval (PMA). FemBloc represents a safer, anesthesia-free alternative to surgical sterilization, an area with virtually no modern innovation.
Pediatrix Medical Group (NYSE:MD) posted Q3 net income of $72 million on $493 million in revenue, with Adjusted EBITDA of $87 million. The company raised its full-year 2025 Adjusted EBITDA outlook to $270–$290 million, citing strong collections, improved patient acuity, and favorable payer mix.
Despite a modest year-over-year revenue decline due to practice dispositions, same-unit revenue rose 8%, underscoring operational consistency and efficiency in a complex healthcare environment.
Investors are watching Caribou Biosciences (NASDAQ:CRBU) ahead of its November 3 webcast, where the company will release new data from its ANTLER and CaMMouflage trials, advancing its next-generation allogeneic CAR-T programs in lymphoma and multiple myeloma.
For more information about Kraig Labs’ spider silk technology and partnership opportunities, visit www.kraiglabs.com
Please click here to read the full Kraig Labs analyst report on 247marketnews.com.
Contact sales@247marketnews.com for Analyst Report coverage and other investor/public relations services.
PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 247 is a third-party media provider and has been compensated for providing ongoing KBLB market outreach and other services.. This press release may include technical analysis and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions. Please review 247’s Full Disclaimer https://www.247marketnews.com/disclaimer/. Please go to https://247marketnews.com/kblb-disclosure/ for further KBLB and 247marketnews.com disclosure information.
The post Breakthrough Biotech Data, Spider Silk Deliveries, and a Strong Quarter in Healthcare appeared first on 24/7 MarketNews.
